BioSyent (CVE:RX) Stock Passes Below 50-Day Moving Average - What's Next?

Key Points

• BioSyent's stock crossed below its 50-day moving average, slipping to C$14.50 versus a 50‑day MA of C$15.11 on a volume of 5,840 shares.
• The company has a market cap of C$165.85 million and a PE of 18.52, with strong liquidity (quick ratio 6.91, current ratio 5.51) but a debt-to-equity ratio of 2.03.
• BioSyent develops and sells pharmaceutical and healthcare products, notably FeraMAX iron therapies, Tibella (tibolone), Inofolic, RepaGyn, and Gelclair.

BioSyent Inc. (CVE:RX - )'s share price crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of C$15.11 and traded as low as C$14.50. BioSyent shares last traded at C$14.50, with a volume of 5,840 shares changing hands.

BioSyent Stock Performance

The company has a quick ratio of 6.91, a current ratio of 5.51 and a debt-to-equity ratio of 2.03. The firm has a 50-day moving average price of C$15.11 and a two-hundred day moving average price of C$13.21. The firm has a market cap of C$165.85 million, a PE ratio of 18.52 and a beta of 1.00.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.